By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...

Pigot most recently served as chief commercial officer at Aerovate Therapeutics, which was developing a dry powder inhaled ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

In people with HIV infection, new-onset diabetes is independently predicted by higher leukocyte counts — mostly within the normal range — and can signal an elevated risk for diabetes.

"The Handmaid's Tale" star O-T Fagbenle reacts to Elisabeth Moss' Emmy snub for show's sixth and final season.

A new school year is set to begin under new roofs for children in pre-kindergarten through sixth grade in Hebron. Hebron Elementary School received a roof replacement in July from contractor Greenwood ...